High-Cost Drug Evaluation: Dutch Institute Redu...

By HEOR Staff Writer

May 4, 2026

In High-Cost Drug Evaluation, the Dutch Healthcare Institute Zorginstituut Nederland, announced that the aver...
NICE Endorses Rozanolixizumab for Myasthenia Gravis Treatment
Dementia Pharmacotherapy Guidelines: Emphasizing Non-Pharmacological Approach...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
Advancing Subcutaneous Diuretic Therapy for Heart Failure Management
Enhancing Breakthrough Medical Device Access: EMA’s New Pilot Program f...
Medical Device Innovation South Africa: Breaking Down Systemic Barriers
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and ...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks ...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Tre...
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application A...